UnitedHealth's shares have pulled back to trade at a 21% discount to their estimated fair value, presenting a buying opportunity. The company is focused on AI-driven efficiencies, exiting unprofitable markets, and value-based care, which supports expected earnings per share growth despite a slight revenue decline projected for 2026. Guidance anticipates at least $17.75 adjusted diluted EPS in 2026, an 8.6% increase, alongside a 3.1% forward dividend yield with strong dividend safety. Risks include minimal rate increases from CMS and ongoing high medical care costs, but UnitedHealth's strong balance sheet and disciplined capital management reinforce its investment appeal.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
